Comparative diagnostic accuracy of multiparametric magnetic resonance imaging-ultrasound fusion-guided biopsy versus systematic biopsy for clinically significant prostate cancer
PeerJ · 2023
DOI: 10.7717/peerj.16614 ↗Kurz gefasst
Fachartikel in der Zeitschrift PeerJ, 2023. Verfasst von Jian-Hua Fang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Ultrasound, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hang Zhou, Zhejiang, China. Hauptthemen laut MEDLINE: Multiparametric Magnetic Resonance Imaging, Prostatic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Construction Fund of Medical Key Disciplines of Hangzhou, Science and Technology Development Project of Hangzhou.
Abstract (Originalsprache)
Purpose
To examine the accuracy of transperineal magnetic resonance imaging (MRI)-ultrasound (US) fusion biopsy (FB) in identifying men with prostate cancer (PCa) that has reached a clinically relevant stage.
Methods
This investigation enrolled 459 males. In 210 of these patients (FB group), transperineal MRI/US fusion-guided biopsies were performed on the suspicious region, and in 249 others, a systematic biopsy (SB) was performed (SB group). We compared these groups using Gleason scores and rates of cancer detection.
Results
PCa cases counted 198/459 (43.1%), including 94/249 (37.8%) in the SB group and 104/210 (49.5%) in the FB group. FB was associated with higher overall diagnostic accuracy relative to SB (88.5% and 72.3%, P = 0.024). FB exhibited greater sensitivity than SB (88.9% and 71.2%, P = 0.025). The area under the curve for FB and SB approaches was 0.837 and 0.737, respectively, such that FB was associated with an 11.9% increase in accuracy as determined based upon these AUC values. Relative to SB, FB was better able to detect high-grade tumors (GS ≥ 7) (78.85% vs . 60.64%, P = 0.025).
Conclusion
Transperineal MRI-US fusion targeted biopsy is superior to the systematic one as an approach to diagnosing clinically significant PCa, as it is a viable technical approach to prostate biopsy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Ultrasound, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hang Zhou, Zhejiang, China.
- Department of Radiology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hang Zhou, Zhejiang, China.
- Department of Urology Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hang Zhou, Zhejiang, China.
- Department of Pathology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hang Zhou, Zhejiang, China.
Förderung
- The Construction Fund of Medical Key Disciplines of Hangzhou
- Science and Technology Development Project of Hangzhou
Zitieren
APA
Fang, J. H., Zhang, L., Xie, X., Zhao, P., Bao, L., & Kong, F. (2023). Comparative diagnostic accuracy of multiparametric magnetic resonance imaging-ultrasound fusion-guided biopsy versus systematic biopsy for clinically significant prostate cancer. PeerJ. https://doi.org/10.7717/peerj.16614
Vancouver
Fang JH, Zhang L, Xie X, Zhao P, Bao L, Kong F. Comparative diagnostic accuracy of multiparametric magnetic resonance imaging-ultrasound fusion-guided biopsy versus systematic biopsy for clinically significant prostate cancer. PeerJ. 2023. doi:10.7717/peerj.16614
BibTeX
@article{Fang2023,
author = {Fang, Jian-Hua and Zhang, Liqing and Xie, Xi and Zhao, Pan and Bao, Lingyun and Kong, Fanlei},
title = {Comparative diagnostic accuracy of multiparametric magnetic resonance imaging-ultrasound fusion-guided biopsy versus systematic biopsy for clinically significant prostate cancer},
journal = {PeerJ},
year = {2023},
doi = {10.7717/peerj.16614}
}
EUVIMED